Stocktoria

Keros Therapeutics, Inc. KROS

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-04-08

Keros Therapeutics, Inc. statistics & valuation

Market cap$217.5M
P / E2.5×
P / S0.9×
P / B0.7×
P / FCF2.1×
Net margin35.7%
Return on equity28.7%
FCF margin43.4%
Return on capital21.3%
Graham number +81.7%$20.36

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($20.36); a green figure means the price is below it.

Profitability & efficiency

Net margin (%)
-123.40% -292.30% -101319.20% -5277.50% 35.70% 2019202020212022202320242025
Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-105.60% -280.50% -112543.70% -5939.00% 27.70% 2019202020212022202320242025
Return on equity (%)
-17.30% -24.20% -37.70% -46.10% -32.80% 28.70% 2019202020212022202320242025
Shares outstanding
2.4M 23.2M 24.0M 27.5M 31.8M 40.6M 37.9M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-112.60% -16.80% -23.00% -34.10% -41.30% -30.40% 25.70% 2019202020212022202320242025
Free cash flow margin (%)
-162.70% -314.30% -84087.40% -4585.90% 43.40% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$2.93 -$2.52 -$4.15 -$5.20 -$5.00 $2.30 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin27.7%-5939.0%-112543.7%—-280.5%—-105.6%
Net margin35.7%-5277.5%-101319.2%—-292.3%—-123.4%
FCF margin43.4%-4585.9%-84087.4%—-314.3%—-162.7%
Return on assets25.7%-30.4%-41.3%-34.1%-23.0%-16.8%-112.6%
Return on equity28.7%-32.8%-46.1%-37.7%-24.2%-17.3%63.4%
Current ratio15.4521.4514.2517.2721.2337.271.99

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.